{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:58:13Z","timestamp":1789534693190,"version":"build-2803163510"},"reference-count":100,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trends in Endocrinology & Metabolism"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.tem.2012.11.007","type":"journal-article","created":{"date-parts":[[2012,12,24]],"date-time":"2012-12-24T23:54:07Z","timestamp":1356393247000},"page":"238-246","source":"Crossref","is-referenced-by-count":131,"title":["Novel pathway for somatostatin analogs in patients with acromegaly"],"prefix":"10.1016","volume":"24","author":[{"given":"M\u00f4nica R.","family":"Gadelha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro","family":"Kasuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rta","family":"Korbonits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tem.2012.11.007_bib0005","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1056\/NEJMra062453","article-title":"Medical progress: acromegaly","volume":"355","author":"Melmed","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tem.2012.11.007_bib0010","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1210\/er.2002-0022","article-title":"Systemic complications of acromegaly: epidemiology, pathogenesis, and management","volume":"25","author":"Colao","year":"2004","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.tem.2012.11.007_bib0015","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1530\/EJE-08-0267","article-title":"A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly","volume":"159","author":"Holdaway","year":"2008","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.tem.2012.11.007_bib0020","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2265.2005.02316.x","article-title":"High prevalence of differentiated thyroid carcinoma in acromegaly","volume":"63","author":"Tita","year":"2005","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"10.1016\/j.tem.2012.11.007_bib0025","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1210\/jc.2008-2421","article-title":"Guidelines for acromegaly management: an update","volume":"94","author":"Melmed","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2012.11.007_bib0030","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11102-010-0232-9","article-title":"Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly","volume":"15","author":"Morin","year":"2012","journal-title":"Pituitary"},{"key":"10.1016\/j.tem.2012.11.007_bib0035","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1210\/jcem-55-3-589","article-title":"Evidence of dopamine receptors in human growth hormone (GH)-secreting adenomas with concomitant study of dopamine inhibition of GH secretion in a perifusion system","volume":"55","author":"Bression","year":"1982","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2012.11.007_bib0040","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1210\/jc.2010-2443","article-title":"Place of cabergoline in acromegaly: a meta-analysis","volume":"96","author":"Sandret","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2012.11.007_bib0045","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000317314","article-title":"Short- and long-term efficacy of combined cabergoline and octreotide treatment in controlling IGF-I levels in acromegaly","volume":"92","author":"Mattar","year":"2010","journal-title":"Neuroendocrinology"},{"issue":"Suppl. 1","key":"10.1016\/j.tem.2012.11.007_bib0050","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1530\/EJE-09-0350","article-title":"The German ACROSTUDY: past and present","volume":"161","author":"Buchfelder","year":"2009","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.tem.2012.11.007_bib0055","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1210\/jc.2011-2508","article-title":"Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY","volume":"97","author":"van der Lely","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2012.11.007_bib0060","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.1210\/jc.2007-1234","article-title":"Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly","volume":"92","author":"Neggers","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2012.11.007_bib0065","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1210\/jc.2005-0260","article-title":"Long-acting somatostatin analog therapy of acromegaly: a meta-analysis","volume":"90","author":"Freda","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2012.11.007_bib0070","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1365-2265.2007.02825.x","article-title":"A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly","volume":"66","author":"Mercado","year":"2007","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"10.1016\/j.tem.2012.11.007_bib0075","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11102-009-0191-1","article-title":"Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension","volume":"13","author":"Melmed","year":"2010","journal-title":"Pituitary"},{"key":"10.1016\/j.tem.2012.11.007_bib0080","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.tem.2009.12.003","article-title":"Pituitary somatostatin receptor signaling","volume":"21","author":"Ben-Shlomo","year":"2010","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.tem.2012.11.007_bib0085","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/frne.1999.0183","article-title":"Somatostatin and its receptor family","volume":"20","author":"Patel","year":"1999","journal-title":"Front. Neuroendocrinol."},{"key":"10.1016\/j.tem.2012.11.007_bib0090","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1210\/jc.2008-1826","article-title":"Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly","volume":"94","author":"Neto","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2012.11.007_bib0095","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1530\/EJE-07-0562","article-title":"Quantitative analysis of somatostatin receptor subtypes (1\u20135) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR","volume":"158","author":"Taboada","year":"2008","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.tem.2012.11.007_bib0100","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1210\/jc.2008-2564","article-title":"Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors","volume":"94","author":"Duran-Prado","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2012.11.007_bib0105","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0024-3205(94)00956-2","article-title":"Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors","volume":"56","author":"Panetta","year":"1995","journal-title":"Life Sci."},{"key":"10.1016\/j.tem.2012.11.007_bib0110","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1210\/jc.2007-1358","article-title":"Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy","volume":"93","author":"Ferone","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2012.11.007_bib0115","unstructured":"Wildemberg, L.E. et al. (2012) Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2, expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs. J. Endocrinol. Invest. http:\/\/www.jendocrinolinvest.it\/jei\/en\/abstract.cfm?articolo_id=8305"},{"key":"10.1016\/j.tem.2012.11.007_bib0120","article-title":"Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly","author":"Gatto","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2012.11.007_bib0125","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1677\/ERC-07-0288","article-title":"Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms","volume":"15","author":"Grozinsky-Glasberg","year":"2008","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.tem.2012.11.007_bib0130","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1111\/j.1582-4934.2010.01125.x","article-title":"Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1 \u2013 molecular pathways","volume":"14","author":"Cakir","year":"2010","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.tem.2012.11.007_bib0135","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.pharmthera.2007.06.010","article-title":"An update on somatostatin receptor signaling in native systems and new insights on their pathophysiology","volume":"116","author":"Cervia","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.tem.2012.11.007_bib0140","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1210\/er.2010-0002","article-title":"Resistance to somatostatin analogs in acromegaly","volume":"32","author":"Colao","year":"2011","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.tem.2012.11.007_bib0145","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1210\/me.2007-0334","article-title":"Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization","volume":"22","author":"Grant","year":"2008","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.tem.2012.11.007_bib0150","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1210\/jc.2009-2247","article-title":"A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs","volume":"95","author":"Duran-Prado","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2012.11.007_bib0155","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/onc.2011.389","article-title":"The new truncated somatostatin receptor variant sst5TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells","volume":"31","author":"Duran-Prado","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.tem.2012.11.007_bib0160","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1210\/jc.86.8.3809","article-title":"Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment","volume":"86","author":"Ballare","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2012.11.007_bib0165","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1210\/jc.2005-0132","article-title":"Analysis of somatostatin receptors 2 and 5 polymorphisms in patients with acromegaly","volume":"90","author":"Filopanti","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2012.11.007_bib0170","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1210\/jc.2009-2197","article-title":"The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response","volume":"95","author":"Fougner","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2012.11.007_bib0175","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1210\/jc.2007-2272","article-title":"Low levels of raf kinase inhibitory protein in growth hormone-secreting pituitary adenomas correlate with poor response to octreotide treatment","volume":"93","author":"Fougner","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2012.11.007_bib0180","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1210\/jc.83.5.1604","article-title":"Pronostic and therapeutic consequences of Gs alpha mutations in somatotroph adenomas","volume":"83","author":"Barlier","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2012.11.007_bib0185","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12022-008-9029-z","article-title":"Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form","volume":"19","author":"Obari","year":"2008","journal-title":"Endocr. Pathol."},{"key":"10.1016\/j.tem.2012.11.007_bib0190","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1365-2265.2011.04163.x","article-title":"Adenoma granulation pattern correlates to clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly","author":"Fougner","year":"2012","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"10.1016\/j.tem.2012.11.007_bib0195","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1507\/endocrj.EJ11-0177","article-title":"Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenomas","volume":"59","author":"Kato","year":"2012","journal-title":"Endocr. J."},{"key":"10.1016\/j.tem.2012.11.007_bib0200","doi-asserted-by":"crossref","first-page":"6290","DOI":"10.1210\/jc.2005-0998","article-title":"The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly","volume":"90","author":"Bhayana","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2012.11.007_bib0205","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2265.2011.04286.x","article-title":"Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly","volume":"77","author":"Heck","year":"2012","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"10.1016\/j.tem.2012.11.007_bib0210","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1210\/jc.2008-0126","article-title":"Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas","volume":"93","author":"Fusco","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2012.11.007_bib0215","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1046\/j.0300-0664.2001.01440.x","article-title":"Men with acromegaly need higher doses of octreotide than women","volume":"56","author":"Engstrom","year":"2002","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"10.1016\/j.tem.2012.11.007_bib0220","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/BF03343583","article-title":"Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide","volume":"22","author":"Suliman","year":"1999","journal-title":"J. Endocrinol. Invest."},{"key":"10.1016\/j.tem.2012.11.007_bib0225","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1210\/jc.80.9.2768","article-title":"Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients \u2013 a clinical research center study","volume":"80","author":"Newman","year":"1995","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2012.11.007_bib0230","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1365-2265.2005.02278.x","article-title":"The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly","volume":"62","author":"Gilbert","year":"2005","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"10.1016\/j.tem.2012.11.007_bib0235","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1590\/S0004-27302005000300010","article-title":"Acute test with subcutaneous octreotide as a predictor of the response to treatment with octreotide LAR","volume":"49","author":"Taboada","year":"2005","journal-title":"Arq. Bras. Endocrinol. Metabol."},{"key":"10.1016\/j.tem.2012.11.007_bib0240","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1073\/pnas.0700004104","article-title":"Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations","volume":"104","author":"Georgitsi","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tem.2012.11.007_bib0245","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1056\/NEJMoa1008020","article-title":"AIP mutation in pituitary adenomas in the 18th century and today","volume":"364","author":"Chahal","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tem.2012.11.007_bib0250","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.tem.2010.02.007","article-title":"Clinical, genetic and molecular characterization of patients with familial isolated pituitary adenomas (FIPA)","volume":"21","author":"Chahal","year":"2010","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.tem.2012.11.007_bib0255","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/humu.21292","article-title":"Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families","volume":"31","author":"Igreja","year":"2010","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.tem.2012.11.007_bib0260","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1126\/science.1126100","article-title":"Pituitary adenoma predisposition caused by germline mutations in the AIP gene","volume":"312","author":"Vierimaa","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.tem.2012.11.007_bib0265","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1210\/jc.2006-2513","article-title":"Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families","volume":"92","author":"Daly","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2012.11.007_bib0270","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/EJE-07-0348","article-title":"The clinical, pathological, and genetic features of familial isolated pituitary adenomas","volume":"157","author":"Beckers","year":"2007","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.tem.2012.11.007_bib0275","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1210\/jc.2007-2611","article-title":"The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas","volume":"93","author":"Leontiou","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2012.11.007_bib0280","doi-asserted-by":"crossref","first-page":"E663","DOI":"10.1210\/jc.2011-2291","article-title":"Germline AIP mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center cohort of 443 patients","volume":"97","author":"Cazabat","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2012.11.007_bib0285","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1530\/EJE-11-0304","article-title":"High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas","volume":"165","author":"Tichomirowa","year":"2011","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.tem.2012.11.007_bib0290","doi-asserted-by":"crossref","first-page":"E373","DOI":"10.1210\/jc.2009-2556","article-title":"Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study","volume":"95","author":"Daly","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2012.11.007_bib0295","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1210\/jc.2006-2702","article-title":"Mutations in the aryl hydrocarbon receptor interacting protein gene are not highly prevalent among subjects with sporadic pituitary adenomas","volume":"92","author":"Barlier","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2012.11.007_bib0300","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1677\/ERC-09-0094","article-title":"Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications","volume":"16","author":"Jaffrain-Rea","year":"2009","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.tem.2012.11.007_bib0305","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1210\/jc.85.2.707","article-title":"Isolated familial somatotropinomas: establishment of linkage to chromosome 11q13.1-11q13.3 and evidence for a potential second locus at chromosome 2p16-12","volume":"85","author":"Gadelha","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2012.11.007_bib0310","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1210\/jc.84.1.249","article-title":"Loss of heterozygosity on chromosome 11q13 in two families with acromegaly\/gigantism is independent of mutations of the multiple endocrine neoplasia type I gene","volume":"84","author":"Gadelha","year":"1999","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2012.11.007_bib0315","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.2353\/ajpath.2010.100138","article-title":"Mice with inactivation of aryl hydrocarbon receptor-interacting protein (Aip) display complete penetrance of pituitary adenomas with aberrant ARNT expression","volume":"177","author":"Raitila","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.tem.2012.11.007_bib0320","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1530\/JOE-11-0054","article-title":"AIP and its interacting partners","volume":"210","author":"Trivellin","year":"2011","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.tem.2012.11.007_bib0325","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1586\/eem.10.42","article-title":"Role of the aryl hydrocarbon receptor-interacting protein in familial isolated pituitary adenoma","volume":"5","author":"Cain","year":"2010","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2012.11.007_bib0330","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1590\/S0004-27302010000800006","article-title":"Familial isolated pituitary adenomas experience at a single center: clinical importance of AIP mutation screening","volume":"54","author":"Pinho","year":"2010","journal-title":"Arq. Bras. Endocrinol. Metabol."},{"key":"10.1016\/j.tem.2012.11.007_bib0335","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1399-0004.2010.01406.x","article-title":"The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes","volume":"78","author":"Stratakis","year":"2010","journal-title":"Clin. Genet."},{"key":"10.1016\/j.tem.2012.11.007_bib0340","doi-asserted-by":"crossref","first-page":"L25","DOI":"10.1530\/ERC-12-0020","article-title":"AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression","volume":"19","author":"Kasuki","year":"2012","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.tem.2012.11.007_bib0345","doi-asserted-by":"crossref","first-page":"E1411","DOI":"10.1210\/jc.2012-1111","article-title":"Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway","volume":"97","author":"Chahal","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2012.11.007_bib0350","first-page":"P1343","article-title":"Aryl hydrocarbon receptor interacting protein in somatotroph adenomas: a molecular target for somatostatin analogues?","volume":"29","author":"Jaffrain-Rea","year":"2012","journal-title":"Endocr. Abstr."},{"key":"10.1016\/j.tem.2012.11.007_bib0355","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000322787","article-title":"Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in Somatotropinomas than Ki-67 and p53","volume":"94","author":"Kasuki Jomori de Pinho","year":"2011","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.tem.2012.11.007_bib0360","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.mce.2010.01.033","article-title":"ZAC1 target genes and pituitary tumorigenesis","volume":"326","author":"Theodoropoulou","year":"2010","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.tem.2012.11.007_bib0365","first-page":"6794","article-title":"The expression of the antiproliferative gene ZAC is lost or highly reduced in nonfunctioning pituitary adenomas","volume":"60","author":"Pagotto","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.tem.2012.11.007_bib0370","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/ijc.24602","article-title":"Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly","volume":"125","author":"Theodoropoulou","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.tem.2012.11.007_bib0375","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1158\/0008-5472.CAN-05-1189","article-title":"Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression","volume":"66","author":"Theodoropoulou","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.tem.2012.11.007_bib0380","first-page":"76","article-title":"Aggression and resistance in somatotropinoma: molecular mechanisms","volume":"5","author":"Theodoropoulou","year":"2012","journal-title":"J. Klin. Endokrinol. Stoffw."},{"key":"10.1016\/j.tem.2012.11.007_bib0385","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1124\/mol.106.029215","article-title":"Endogenous hepatic expression of the hepatitis B virus X-associated protein 2 is adequate for maximal association with aryl hydrocarbon receptor\u201390-kDa heat shock protein complexes","volume":"70","author":"Hollingshead","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.tem.2012.11.007_bib0390","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.2353\/ajpath.2009.081131","article-title":"The expression of AIP-related molecules in elucidation of cellular pathways in pituitary adenomas","volume":"175","author":"Heliovaara","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.tem.2012.11.007_bib0395","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1210\/me.11.7.859","article-title":"Somatostatin acts by inhibiting the cyclic 3\u2032,5\u2032-adenosine monophosphate (cAMP)\/protein kinase A pathway, cAMP response element-binding protein (CREB) phosphorylation, and CREB transcription potency","volume":"11","author":"Tentler","year":"1997","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.tem.2012.11.007_bib0400","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.mce.2007.09.009","article-title":"Selective agonism in somatostatin receptor signaling and regulation","volume":"286","author":"Schonbrunn","year":"2008","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.tem.2012.11.007_bib0405","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1152\/jn.00872.2006","article-title":"Mechanism of spontaneous and receptor-controlled electrical activity in pituitary somatotrophs: experiments and theory","volume":"98","author":"Tsaneva-Atanasova","year":"2007","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.tem.2012.11.007_bib0410","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1210\/jc.84.8.2759","article-title":"Impact of gsp oncogene on the expression of genes coding for Gsalpha, Pit-1, Gi2alpha, and somatostatin receptor 2 in human somatotroph adenomas: involvement in octreotide sensitivity","volume":"84","author":"Barlier","year":"1999","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2012.11.007_bib0415","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0303-7207(87)90052-9","article-title":"A comparison of the effects of bromocriptine and somatostatin on growth hormone gene expression in the rat anterior pituitary gland in vitro","volume":"52","author":"Wood","year":"1987","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.tem.2012.11.007_bib0420","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.mce.2012.05.020","article-title":"Somatostatin analogs and chimeric somatostatin\u2013dopamine molecules differentially regulate human growth hormone and prolactin gene expression and secretion in vitro","volume":"362","author":"Gruszka","year":"2012","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.tem.2012.11.007_bib0425","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.mce.2007.08.012","article-title":"Somatostatin\/somatostatin receptor signalling: phosphotyrosine phosphatases","volume":"286","author":"Florio","year":"2008","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.tem.2012.11.007_bib0430","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1210\/me.8.10.1289","article-title":"The somatostatin receptor SSTR1 is coupled to phosphotyrosine phosphatase activity in CHO-K1 cells","volume":"8","author":"Florio","year":"1994","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.tem.2012.11.007_bib0435","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1073\/pnas.91.6.2315","article-title":"Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2","volume":"91","author":"Buscail","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tem.2012.11.007_bib0440","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1210\/me.13.1.24","article-title":"Somatostatin activation of mitogen-activated protein kinase via somatostatin receptor 1 (SSTR1)","volume":"13","author":"Florio","year":"1999","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.tem.2012.11.007_bib0445","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrc1837","article-title":"Protein-tyrosine phosphatases and cancer","volume":"6","author":"Ostman","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.tem.2012.11.007_bib0450","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1210\/en.2005-0001","article-title":"SRC homology-2-containing protein tyrosine phosphatase-1 restrains cell proliferation in human medullary thyroid carcinoma","volume":"146","author":"Zatelli","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.tem.2012.11.007_bib0455","doi-asserted-by":"crossref","first-page":"15186","DOI":"10.1074\/jbc.274.21.15186","article-title":"sst2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1). Evidence for the role of SHP-1","volume":"274","author":"Pages","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tem.2012.11.007_bib0460","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/eje.1.02213","article-title":"Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours","volume":"155","author":"Hubina","year":"2006","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.tem.2012.11.007_bib0465","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/sj.cdd.4401939","article-title":"Novel synergistic mechanism for sst2 somatostatin and TNFalpha receptors to induce apoptosis: crosstalk between NF-kappaB and JNK pathways","volume":"14","author":"Guillermet-Guibert","year":"2007","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.tem.2012.11.007_bib0470","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1677\/erc.1.01191","article-title":"Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2","volume":"13","author":"Ferrante","year":"2006","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.tem.2012.11.007_bib0475","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000054675","article-title":"Vascular endothelial growth factor production and regulation in rodent and human pituitary tumor cells in vitro","volume":"74","author":"Lohrer","year":"2001","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.tem.2012.11.007_bib0480","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1677\/ERC-06-0026","article-title":"Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion","volume":"14","author":"Zatelli","year":"2007","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.tem.2012.11.007_bib0485","doi-asserted-by":"crossref","first-page":"7951","DOI":"10.1073\/pnas.122062299","article-title":"Direct, activating interaction between glycogen synthase kinase-3beta and p53 after DNA damage","volume":"99","author":"Watcharasit","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tem.2012.11.007_bib0490","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3109\/07357907.2010.494318","article-title":"CRH and SRIF have opposite effects on the Wnt\/beta-catenin signalling pathway through PKA\/GSK-3beta in corticotroph pituitary cells","volume":"28","author":"Khattak","year":"2010","journal-title":"Cancer Invest."},{"key":"10.1016\/j.tem.2012.11.007_bib0495","first-page":"126","article-title":"Octreotide inhibits growth of colonic cancer SW480 cells by modulating the Wnt\/P-catenin pathway","volume":"64","author":"Chen","year":"2009","journal-title":"Pharmazie"},{"key":"10.1016\/j.tem.2012.11.007_bib0500","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1210\/en.2007-0542","article-title":"Wnt pathway inhibitors are strongly down-regulated in pituitary tumors","volume":"149","author":"Elston","year":"2008","journal-title":"Endocrinology"}],"container-title":["Trends in Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043276012002172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043276012002172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T18:04:01Z","timestamp":1539972241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043276012002172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":100,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S1043276012002172"],"URL":"https:\/\/doi.org\/10.1016\/j.tem.2012.11.007","relation":{},"ISSN":["1043-2760"],"issn-type":[{"value":"1043-2760","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}